EX-10.1



 Exhibit 10.1 
  

					
		  	 Confidential Materials omitted and filed separately with the

Securities and Exchange Commission. Double asterisks denote omissions.
	 	

 Amendment to 

Collaboration and License Agreement 

This Amendment (this “Amendment”) to the Collaboration and License Agreement dated as of February 20, 2014 and
previously amended on July 23, 2013 (collectively, the “Agreement”), by and between EPIZYME and GSK is effective as of the date of last signature below (the “Amendment Effective Date”). Capitalized terms used but not
defined herein shall have the meanings ascribed to such terms in the Agreement. 
 WHEREAS, pursuant to the Agreement, the Parties agreed to
conduct certain Development activities including activities with respect to the Selected Target [**] under a Research Plan, and EPIZYME granted to GSK an exclusive worldwide license to Develop and Commercialize certain compounds directed to the
Selected Target [**], 
 WHEREAS, the Parties desire to clarify and supplement the activities of the Parties under the Research Plan. 

NOW, THEREFORE, in consideration of the mutual covenants contained herein, and for other good and valuable consideration, the Parties,
intending to be legally bound, hereby agree as follows: 
 1. Amendment of Section 4.3. Section 4.3 of the
Agreement is hereby amended by inserting the following new Section 4.3.1 immediately following Section 4.3 of the Agreement: 

4.3.1 Disclosure of Licensed Compound Structures. Notwithstanding anything to the contrary in the Agreement, including
Articles 4, 5, and 6, the Parties agree that: 
 (a) EPIZYME will waive the right to redact the chemical structure of any
Compound prior to such Compound’s achievement of the Lead Candidate Criteria for all compounds directed to [**] that meet the Licensed Compound definition of Section 1.63 of the Agreement. Disclosure of the chemical structures of all such
Licensed Compounds determined as of the Amendment Effective Date will occur immediately. Disclosure of the chemical structures of all Licensed Compounds determined from and after the Amendment Effective Date and prior to Development Candidate
Selection (or the end of the Research Term if prior to Development Candidate Selection) will occur on a regular schedule every [**] after the Amendment Effective Date. For the avoidance of doubt, from and after the Amendment Effective Date and prior
to Development Candidate Selection (or the end of the Research Term if prior to Development Candidate Selection), GSK and its Affiliates and Sublicensees shall not conduct any chemistry activities based on the chemical structures of the Licensed
Compounds. 
 (b) Any compounds derived from chemistry activities conducted by GSK or its Affiliates or Sublicensees prior to
Development Candidate Selection (or the end of the Research Term if prior to Development Candidate Selection) based on the chemical structures of Licensed Compounds disclosed to GSK by EPIZYME under subsection (a) above, shall be deemed to be
EPIZYME IP for all purposes under the Agreement. 
 2. Miscellaneous. The Parties hereby confirm and agree that, as
amended herein, the Agreement remains in full force and effect. This Amendment may be executed in counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Facsimile signatures
and signatures transmitted via PDF shall be treated as original signatures. 







 IN WITNESS WHEREOF, the Parties have caused this Amendment to be executed by their duly
authorized representatives. 
  

									
	EPIZYME, INC.	 		 	GLAXO GROUP LIMITED
					
	By:	 	 /s/ Jason Rhodes
	 		 	By:	 	 /s/ RK Prinjha

	Name:	 	Jason Rhodes	 		 	Name:	 	 RK Prinjha

	Title:	 	President & CFO	 		 	Title:	 	 VP Head Epinova DPU, GSK

	Date:	 	 2/24/14
	 		 	Date:	 	 21st February 2014